| Name | Title | Contact Details |
|---|
Every day` 119`000 compassionate caregivers serve patients and communities through Providence St. Joseph Health` a national` Catholic` not-for-profit health system` driven by a belief that health is a human right. Rooted in the founding missions of the Sisters of Providence and the Sisters of St. Joseph of Orange` courageous women ahead of their time who brought health care and other social services to the American West when it was still a rugged` untamed frontier` we share a singular commitment to improve the health of all. From our earliest days` we’ve met new challenges by pioneering new solutions. Today` with 51 hospitals` 829 clinics and a comprehensive range of services` we strive to meet the needs of communities across Alaska` California` Montana` New Mexico` Oregon` Texas and Washington through a diverse family of Catholic` other faith-based and mission-driven secular organizations. Now` as we face a new frontier—a changing health care landscape—we draw upon their pioneering and compassionate spirit to plan for the next century of health for a better world` especially for the poor and vulnerable. If you need treatment` please visit www.providence.org to locate a health care provider.
Graham Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Graham Hospital is based in Canton, IL. You can find more information on Graham Hospital at www.grahamhospital.org
Pharmacyclics is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Sunnyvale, CA. To find more information about Pharmacyclics, please visit www.pcyc.com
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.
ZoomMed inc. is a Brossard, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.